News >

Novel Drugs Revolutionizing ROS1+ and ALK+ NSCLC

Jessica Hergert
Published: Thursday, Oct 10, 2019

Katie Kerrigan, MD, a hematology/oncology fellow at the University of Utah School of Medicine

Katie Kerrigan, MD

Following the 2016 FDA approval of crizotinib (Xalkori), agents designed to target ROS1-mutated advanced non–small cell lung cancer (NSCLC) have been rapidly emerging and showing impressive signals of activity, said Katie Kerrigan, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Experts Weigh-In on Emerging Immune Checkpoint Inhibitors and Combination Strategies for Advanced NSCLCNov 30, 20191.5
Burst CME™ – Cancer Summaries and Commentaries: Update from Toronto: Advances in the Treatment of Lung CancersNov 30, 20190.5
Publication Bottom Border
Border Publication
x